Due to its spatiotemporal resolution, penetration depth, sensitivity and specificity, optoacoustic imaging (OAI) can be used for a multitude of applications, for both preclinical and clinical research:
In the past 5-10 years, OAI has become an established imaging modality for in vivo preclinical research. Based on its unique ability to differentiate endogenous chromophores and exogenous probes, a wide variety of applications has been successfully explored.
Following the success of OAI in preclinical research, the technology has already transitioned into clinical research use. Key areas of interest include oncology, inflammation and fibrosis. Results obtained so far support a bright future for OAI in clinical diagnosis.
The Munich-based biomedical imaging company was awarded the CE Mark for its MSOT Acuity Echo imaging system, indicating conformity with health, safety and environmental protection
Patients with the chronic condition IBD undergo recurring phases of inflammation and remission of the gastrointestinal tract. In treatment management of IBD, it is necessary
06.10.2021 – 09.10.2021 // Miami, Florida (USA)
16.02.2022 – 19.02.2022 // Vienna (Austria)
15.03.2022 – 18.03.2022 // Thessaloniki (Greece)
If you have any questions about our technology, applications or products, don’t hesitate to get in touch.
powered by Borlabs Cookie